Continuous or Split-Course Combined External and Intracavitary Radiotherapy of Locally Advanced Carcinoma of the Uterine Cervix

Pedersen, Dorte; Bentzen, Søren M.; Overgaard, Jens

doi:10.3109/02841869409083934

Cited by 11 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several examples in other cancer types, associated with reduced toxicity while maintaining efficacy (Pradier et al , 2004; Metcalfe et al , 2010; Fukuda et al , 2012; Gogna et al , 2012). The high metabolic response rates of the primary rectal cancer reported here support that this strategy warrants further study, but it should also be noted that split-course radiation was reported to have a negative impact in head and neck (Daoud et al , 2007; Miszczyk et al , 2014), gynaecological (Pedersen et al , 1994), and anal cancers (John et al , 1996). …”

Section: Discussionsupporting

confidence: 59%

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

et al. 2014

View full text Add to dashboard Cite

Background:Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control. Chemotherapy used during chemoradiotherapy (CRT) is adequate for radiosensitisation, but suboptimal for systemic control. The aim of this phase II study was to assess tolerability, local/systemic benefits, of a novel regimen delivering interdigitating intensive chemotherapy with radical CRT.Methods:Eligible pts had untreated synchronous symptomatic primary/metastatic rectal cancer. A total of 12 weeks of treatment with split-course pelvic CRT (total 50.4 Gy with concurrent oxaliplatin and 5-FU infusion) alternating with FOLFOX chemotherapy. All pts staged with CT, MRI and FDG-PET pre and post treatment.Results:Twenty-six pts were treated. Rectal primary MRI stage: T3 81% and T4 15%. Liver metastases in 81%. Twenty-four pts (92%) completed the 12-week regimen. All patients received planned RT dose, and for both agents over 88% of patients achieved a relative dose intensity of >75%. Grade 3 toxicities: neutropenia 23%, diarrhoea 15%, and radiation skin reaction 12%. Grade 4 toxicity: neutropenia 15%. FDG-PET metabolic response rate for rectal primary 96%, and for metastatic disease 60%.Conclusions:Delivery of interdigitating chemotherapy with radical CRT was feasible to treat both primary and metastatic rectal cancer. High completion and response rates were encouraging.

show abstract

Section: Discussionsupporting

confidence: 59%

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This was also seen in the study by Routledge et al, in (2003) where the average overall subjective score rose significantly with advancing stage. It has also been recognized by Pedersen et al, (1994) that advancing stage of disease increases late morbidity after pelvic radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Urinary Dysfunction Assessment in Long-Term Survivors of Carcinoma Cervix Using LENT SOMA Scale: An Indian Study Addressing Quality of Life Issues

Shankar

Patil

Sethi

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background:Carcinoma cervix is the second most common type of cancer in the world. With the increasing proportion of women surviving carcinoma of the cervix, quality of life has been an important clinical issue. Since there are very few studies from India, this study is to assess urinary dysfunction issues in patients of carcinoma cervix treated with multimodality therapy using the LENT SOMA scores. Methods:The study was prospective and patients treated between 1995 - 2007 on follow up were included in this study after ethical clearance. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty-six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to post-operative radiotherapy. The mean age was 47.81 years with a range of 25-68 years. Completion of LENT SOMA scale and Statistical analysis was done. Results:Mean score for BU (Bladder/Urethra) was highest (0.0758) in fifth year of treatment whereas UK (Ureter/Kidney score was highest (0.0408) after 4 years. Bladder score was more in 60-69 years of age and in stage IIIB patients of cervical cancers. Bladder morbidity was more in patients who received chemoradiotherapy and in patients who received radiotherapy with boost where Bladder and Urethra morbidity was more in patients who were treated with Extended Field radiation. Conclusions:The LENT SOMA system was acceptable and feasible to use and gave us an insight into the morbidity in our patients and to develop effective management plans to reduce the post treatment symptoms and improve quality of life.

show abstract

“…extending treatment time from a little more than 1 month to almost 3 months, came in general use in Radiumstationen in Aarhus in 1978. When the experience from this was analyzed (66), it was found that the therapeutic ratio between tumor control and recto-sigmoid complications was reduced relative to that of a continuous-course schedule.…”

Section: From Split-course To Accelerated Fractionation: the Tumor Timentioning

confidence: 99%

A 100-Year Nordic Perspective On The Dose-Time Problem In Radiobiology

Bentzen

1995

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

Continuous or Split-Course Combined External and Intracavitary Radiotherapy of Locally Advanced Carcinoma of the Uterine Cervix

Cited by 11 publications

References 33 publications

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

Urinary Dysfunction Assessment in Long-Term Survivors of Carcinoma Cervix Using LENT SOMA Scale: An Indian Study Addressing Quality of Life Issues

A 100-Year Nordic Perspective On The Dose-Time Problem In Radiobiology

Contact Info

Product

Resources

About